"Black box" warning needed for Flomax before cataract surgery?
This article was originally published in Scrip
Experts have called for stronger warnings for patients receiving Boehringer Ingelheim's benign prostatic hyperplasia (BPH) treatment Flomax (tamsulosin) when they are undergoing cataract surgery, as it has been found to increase the risk of serious postoperative ophthalmic adverse events, including intra-operative floppy iris syndrome (IFIS).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.